FDA approves up to date labeling for Talzenna plus Xtandi in males with HRR gene-mutated metastatic prostate most cancers: © inventory.adobe.com.
The U.S. Meals and Drug Administration (FDA) authorized up to date labeling for Talzenna (talazoparib) plus Xtandi (enzalutamide) for males with homologous recombination restore (HRR) gene-mutated metastatic castration-resistant prostate most cancers, however didn’t broaden its use to non-HRR gene mutations, in accordance with a information launch from Pfizer.
The FDA’s determination to replace the label for Talzenna and Xtandi was based mostly on information from the part 3 TALAPRO-2 trial. Outcomes confirmed a statistically vital and clinically significant enchancment in general survival for this group. At a median follow-up of 44.2 months, median general survival was 45.1 months for these receiving Talzenna and Xtandi versus 31.1 months within the Xtandi and placebo group; this interprets to a 14-month enchancment and a 38% discount within the threat of dying.
Nonetheless, the FDA additionally said that the trial didn’t assist increasing the indication to incorporate sufferers with out these mutations, and Pfizer won’t pursue that growth in america.
For extra info on the trial and efficacy outcomes, watch Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, on the Norton Healthcare Institute, in Louisville, Kentucky, talk about the TALAPRO-2 trial as the largest takeaway from the 2025 Annual ASCO Genitourinary (GU) Cancers Symposium when it comes to prostate most cancers therapy.
“Males with metastatic castration-resistant prostate most cancers are sometimes confronted with a poor prognosis and restricted therapy choices, and Talzenna together with Xtandi has redefined the standard-of-care for sufferers residing with HRR gene-mutated metastatic castration-resistant prostate most cancers,” Dr. Johanna Bendell, oncology chief improvement officer, Pfizer, mentioned within the information launch. “We’re happy that the statistically vital remaining general survival information reaffirming the present indication has been added to the label, based mostly on the sturdy outcomes from TALAPRO-2.”
Glossary:
General survival: time from therapy begin till dying from any trigger.
Radiographic progression-free survival: time from randomization till radiographic proof of most cancers development or dying.
Goal response price: share of sufferers whose most cancers shrinks or disappears after therapy.
Length of response: size of time most cancers stays managed after preliminary response to therapy.
Prostate-specific antigen response: discount in prostate-specific antigen ranges indicating therapy effectiveness.
The part 3 TALAPRO-2 trial evaluated therapy for metastatic castration-resistant prostate most cancers in sufferers who had not acquired newer life-prolonging therapies. This world research enrolled 1,035 sufferers throughout the U.S., Canada, Europe, South America and the Asia-Pacific area. Individuals have been divided into two teams: an unselected group of 805 sufferers, which included 169 with homologous recombination restore gene mutations, and a second group of 399 sufferers with HRR mutations, combining the 169 from the primary group with 230 further sufferers. Sufferers have been randomly assigned to obtain both Talzenna with Xtandi or a placebo with Xtandi.
General survival was a deliberate key secondary endpoint within the research. The first finish level was radiographic progression-free survival, measured from randomization to the primary radiographic development or dying. This utilized to each the unselected group and the group with homologous recombination restore mutations. Different secondary finish factors included goal response price, length of response, prostate-specific antigen response, time to chemotherapy and progression-free survival after the subsequent therapy.
What’s Talzenna and its Earlier FDA Indications?
Talzenna (talazoparib) is an oral drug that blocks poly ADP-ribose polymerase, an enzyme concerned in repairing broken DNA. By inhibiting this enzyme and trapping it at websites of DNA injury, Talzenna reduces most cancers cell progress and results in most cancers cell dying. This motion makes it efficient towards cancers with defects in DNA restore.
Talzenna was first authorized as a single therapy for adults with HER2-negative regionally superior or metastatic breast most cancers who’ve dangerous or suspected dangerous germline BRCA mutations. Sufferers are chosen for this therapy based mostly on a government-approved check that detects these mutations.
In June 2023, the FDA authorized Talzenna mixed with Xtandi for adults with metastatic castration-resistant prostate most cancers that has mutations in homologous recombination restore genes. This mix works by concentrating on each DNA restore pathways and androgen receptor signaling to gradual most cancers progress. The European Fee adopted with approval in January 2024 for sufferers with metastatic castration-resistant prostate most cancers who usually are not candidates for chemotherapy. Talzenna is the primary drug of its variety authorized within the European Union for use with Xtandi for prostate most cancers, no matter gene mutation standing.
Right this moment, Talzenna plus Xtandi is authorized in additional than 40 nations worldwide for superior prostate most cancers, although precise makes use of differ by area. This mix supplies a brand new therapy possibility for sufferers with superior prostate most cancers who’ve restricted therapies out there, as per the discharge.
Reference:
“Pfizer supplies replace on U.S. regulatory evaluation of Talzenna together with Xtandi for broader use in metastatic castration-resistant prostate most cancers,” Pfizer Inc., June 13, 2025.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
